A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients with Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Recruiting

Phase 2

CanakinumabA Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients with Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT04239157

Conditions

Chronic Myelomonocytic Leukemia

Myelodysplastic Syndrome

Recurrent Chronic Myelomonocytic Leukemia

Recurrent Myelodysplastic Syndrome

Refractory Chronic Myelomonocytic Leukemia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Canakinumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-01. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2024-10-17.